Novartis’ Zykadia Sets New “Breakthrough” Speed Record For NME Review

FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.